ALNYLAM PHARMACEUTICALS, INC. (ALNY) Form 8-K — Oct 29, 2026
Alnylam Pharmaceuticals reported Q3 2026 global net product revenues of $1,292 million, up 52% year over year, driven by total TTR revenues of $1,150 million (59% growth) led by AMVUTTRA at $1,130 million (+65%). GAAP net income was $2.17 billion ($15.72 diluted EPS) versus $292.7 million a year ago, boosted by a $1.9 billion tax benefit from the release of deferred tax asset valuation allowances; non-GAAP diluted EPS was $16.26. Total revenues rose 17% to $1.46 billion while royalty revenue more than doubled to $94.7 million on Leqvio sales.
Key figures
- Eps
- GAAP diluted $15.72; non-GAAP diluted $16.26
- Revenue
- 1458086000
- Guidance
- FY2026 reiterated: total net product revenues $4,700M-$5,100M; total TTR net product revenues $4,200M-$4,500M; total Rare net product revenues $500M-$600M; net revenues from collaborations and royalties $575M-$625M; non-GAAP R&D and SG&A expenses $2,700M-$2,800M
- Net Income
- GAAP $2,167,335K; non-GAAP $2,241,910K
- Revenue Yoy
- 17%
- Total Assets
- 7994672000
- Cash Position
- cash, cash equivalents and marketable securities of $3.6 billion
- Shares Outstanding
- 133875000
- Tax Benefit Q3
- 1871525000
- Gaap Net Income
- 2167335000
- Gaap Diluted Eps
- 15.72
- Royalty Revenue
- 94664000
- Oxlumo Q3 Revenue
- 52500000
- Non Gaap Net Income
- 2241910000
- Amvuttra Growth Yoy
- 65%
- Amvuttra Q3 Revenue
- 1130363000
- Givlaari Q3 Revenue
- 89487000
- Non Gaap Diluted Eps
- 16.26
- Onpattro Change Yoy
- (50)%
- Onpattro Q3 Revenue
- 19596000
- Total Ttr Growth Yoy
- 59%
- Net Product Revenues
- 1291946000
- Total Rare Growth Yoy
- 12%
- Collaboration Revenue
- 71476000
- Royalty Revenue Growth Yoy
- 105%
- Gaap Income From Operations
- 345798000
- Net Product Revenue Growth Yoy
- 52%
- Total Ttr Net Product Revenues
- 1149959000
- Non Gaap Income From Operations
- 424916000
- Total Rare Net Product Revenues
- 141987000
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.